PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 4, 2026Neurology and Therapy3 citationsOpen Access

Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg

FDFlora D’AmicoSCSofia CampoNRNicasio Rini

Key Points

  • The research aims to evaluate the effectiveness of efgartigimod in patients with generalized myasthenia gravis who are refractory or intolerant to IVIg.
  • Real-world cohort analysis
  • Assessment of clinical benefit
  • Evaluation of tolerability profile
  • Efgartigimod showed rapid clinical benefits
  • Favorable tolerability profile observed
  • Potential as an effective therapy after IVIg failure or intolerance

Abstract

In this real-world cohort, efgartigimod demonstrated a rapid and meaningful clinical benefit with a favorable tolerability profile in patients with AChR-positive gMG after IVIg failure or intolerance. These findings support the potential role of EFG as an effective therapeutic option in this difficult-to-treat population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

D’Amico et al. (2026) studied this question.

synapsesocial.com/papers/69d0adc2659487ece0fa44d8https://doi.org/10.1007/s40120-026-00923-1
Ask AI
Helpful
Bookmark
Share
View Full Paper